Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice

Am J Physiol Lung Cell Mol Physiol. 2015 Jul 15;309(2):L158-67. doi: 10.1152/ajplung.00338.2014. Epub 2015 May 22.

Abstract

Suppression of type 17 immunity by type I interferon (IFN) during influenza A infection has been shown to enhance susceptibility to secondary bacterial pneumonia. Although this mechanism has been described in coinfection with gram-positive bacteria, it is unclear whether similar mechanisms may impair lung defense against gram-negative infections. Furthermore, precise delineation of the duration of type I IFN-associated susceptibility to bacterial infection remains underexplored. Therefore, we investigated the effects of preceding influenza A virus infection on subsequent challenge with the gram-negative bacteria Escherichia coli or Pseudomonas aeruginosa and the temporal association between IFN expression with susceptibility to Staphylococcus aureus challenge in a mouse model of influenza and bacterial coinfection. Here we demonstrate that preceding influenza A virus led to increased lung E. coli and P. aeruginosa bacterial burden, which was associated with suppression of type 17 immunity and attenuation of antimicrobial peptide expression. Enhanced susceptibility to S. aureus coinfection ceased at day 14 of influenza infection, when influenza-associated type I IFN levels had returned to baseline levels, further suggesting a key role for type I IFN in coinfection pathogenesis. These findings further implicate type I IFN-associated suppression of type 17 immunity and antimicrobial peptide production as a conserved mechanism for enhanced susceptibility to both gram-positive and gram-negative bacterial coinfection during influenza infection.

Keywords: Escherichia coli; Staphylococcus aureus; coinfection; influenza A; type I interferon.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimicrobial Cationic Peptides / metabolism
  • Coinfection / immunology
  • Coinfection / microbiology
  • Coinfection / virology
  • Disease Susceptibility
  • Escherichia coli / immunology
  • Escherichia coli / pathogenicity
  • Escherichia coli Infections / immunology
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Infections / virology
  • Influenza A virus / immunology
  • Influenza A virus / pathogenicity*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Orthomyxoviridae Infections / immunology
  • Orthomyxoviridae Infections / microbiology*
  • Orthomyxoviridae Infections / virology
  • Pneumonia / immunology
  • Pneumonia / microbiology*
  • Pneumonia / virology
  • Pneumonia, Bacterial / immunology
  • Pneumonia, Bacterial / microbiology*
  • Pneumonia, Bacterial / virology
  • Receptor, Interferon alpha-beta / physiology*
  • Staphylococcal Infections / immunology
  • Staphylococcal Infections / microbiology*
  • Staphylococcal Infections / virology
  • Staphylococcus aureus / immunology
  • Staphylococcus aureus / pathogenicity

Substances

  • Antimicrobial Cationic Peptides
  • Ifnar1 protein, mouse
  • Receptor, Interferon alpha-beta